CONTINUING MEDICAL EDUCATION
Continuing Nursing Education
This program is accredited for a maximum of 24 contact hours (This includes a maximum of 18 contact hours and 6 pharmacology contact hours for the general sessions and a maximum of 3 contact hours for each workshop. The EKG workshop will provide up to .25 pharmacology contact hours and the kidney workshop will provide up to 1.0 pharmacology contact hours) in partnership with Partners in Healthcare Education, LLC. Partners in Healthcare Education, LLC, is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number 031206.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
The University of Cincinnati designates this Live Activity for a maximum of 24 AMA PRA Category 1 Credits™ (a maximum of 18 credits for the general sessions and a maximum of 6 credits for the workshops). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants Credit Designation
The American Academy of Physician’s Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME.
Overall Learning Objectives:
After completing this live activity, participants should be able to:
- Analyze disease patterns and apply pattern recognition to the clinical evaluation and differential diagnoses in patients with respiratory disease and cardiovascular disease (CVD).
- Integrate into daily practice evidence-based recommendations for the clinical management of respiratory disease and CVD, including aggressive treatment and treatment-to-target strategies.
- Evaluate the safety and efficacy of pharmacotherapy in the treatment of chronic obstructive pulmonary disease (COPD), asthma, sinusitis, hypertension, dyslipidemia, thyroid and heart, renal disease, coronary artery diseases (CAD), heart failure, valvular heart disease and endocarditis.
- Discuss the currently available and emerging medications that target established and newly recognized pathways in the pathogenesis of respiratory disease and CVD.
- Incorporate new therapies in appropriately selected patients.
- Provide evidence-based patient education on treatment options, use of inhalers and breathing aids, and the role of home care.
- Review routine practice protocols for use of the most appropriate outcomes measures
- Formulate evidence-based lifestyle management plans incorporating updated recommendations for patients with respiratory disease and CVD.
- Develop individualized strategies for respiratory and cardiovascular therapy.
- Recognize the need for referral to a pulmonologist or cardiologist and understand the role of appropriate handoff, documentation and communication in the referral process.